J. Doody

发表

Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

P. Bohlen, P. Kussie, A. Kiselyov, 2009, Bioorganic & medicinal chemistry.

Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway

J. Massagué, Joan Massagué, J. Doody, 1999, Nature.

Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

F. Liao, D. Hicklin, P. Bohlen, 2002, Cancer Research.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer Research.

Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.

A. Malikzay, P. Kussie, M. C. Tuma, 2010, Translational oncology.

Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy.

M. C. Tuma, A. Kiselyov, Ying Wang, 2010, ACS medicinal chemistry letters.

Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines.

A. Malikzay, M. C. Tuma, A. Kiselyov, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors.

A. Malikzay, P. Kussie, M. C. Tuma, 2005, Bioorganic & medicinal chemistry letters.

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

L. Young, Sarah Batey, N. Brewis, 2020, Clinical Cancer Research.

J Massagué receptor model to the BMPs . proteins ( BMPs ) : extension of the two-kinase Human type II receptor for bone morphogenic

F. Ventura, F. Liu, J. Doody, 1995 .

Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation

Zhen-ping Zhu, K. Paz, Michelle Iacolina, 2005, Molecular Cancer Therapeutics.

Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.

A. Kiselyov, Leon M. Smith, M. Duncton, 2006, Bioorganic & medicinal chemistry letters.

Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.

J. Massagué, William Arbuthnot Sir Lane, F. López‐Casillas, 1991, Cell.

Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase.

A. Kiselyov, Leon M. Smith, Yongjiang Xu, 2006, Bioorganic & medicinal chemistry letters.

Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.

Xin Chen, A. Kiselyov, Leon M. Smith, 2006, Bioorganic & medicinal chemistry letters.

Synthesis of polysubstituted 4-fluoroquinolinones.

A. Kiselyov, J. Doody, Evgueni L. Piatnitski, 2004, Organic letters.

Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs

J. Massagué, F. Ventura, F. Liu, 1995, Molecular and cellular biology.

Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.

A. Kiselyov, M. Duncton, R. Katoch-Rouse, 2005, Bioorganic & medicinal chemistry letters.

Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system

J. Massagué, William Arbuthnot Sir Lane, F. López‐Casillas, 1991, Cell.

Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.

A. Kiselyov, M. Duncton, R. Katoch-Rouse, 2005, Bioorganic & medicinal chemistry letters.

A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras.

J. Massagué, M. Kretzschmar, J Massagué, 1999, Genes & development.

A human Mad protein acting as a BMP-regulated transcriptional activator

J. Massagué, J. Baker, A. Hata, 1996, Nature.

TGFβ signals through a heteromeric protein kinase receptor complex

Jeffrey L. Wrana, Liliana Attisano, J. Massagué, 1992, Cell.

The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase.

J. Massagué, A. Hata, M. Kretzschmar, 1997, Genes & development.

TGF beta signals through a heteromeric protein kinase receptor complex.

J. Massagué, J. Wrana, M. Laiho, 1992, Cell.

Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.

F. Liao, D. Hicklin, P. Bohlen, 2005, Blood.

Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1

M. Kretzschmar, J. Doody, J. Massagu, 1997, Nature.

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhen-ping Zhu, Yan Wu, D. Ludwig, 2010, Clinical Cancer Research.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers

D. Hicklin, Sheetal Patel, Y. Hadari, 2007, Molecular Cancer Therapeutics.

Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.

J. Massagué, J Massagué, J Doody, 1999, Nature.

Interaction of Transforming Growth Factor-β Receptor I with Farnesyl-protein Transferase-α in Yeast and Mammalian Cells*

J. Massagué, F. Ventura, J. Doody, 1996, The Journal of Biological Chemistry.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Anticorps contre le csf-1r

J. Doody, Yanxia Li, 2011 .

Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics.

J. Doody, Miguel Gaspar, K. L. Everett, 2019, Methods.

OpposingBMPandEGF signallingpathways convergeon theTGF-b familymediatorSmad 1

J. Massagué, M. Kretzschmar, J. Doody, 1997 .

Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses

L. Young, N. Brewis, J. Doody, 2018, Immunology.

Reconstitution and transphosphorylation of TGF‐beta receptor complexes.

J. Massagué, J. Wrana, F. Ventura, 1994, The EMBO journal.

Signal transduction and gene expression in Dictyostelium discoideum

B. Haribabu, R. Dottin, J. Doody, 1991 .

Signal transduction pathways involved in the expression of the uridine diphosphoglucose pyrophosphorylase gene of Dictyostelium discoideum.

B. Haribabu, J. Pavlovic, R. Dottin, 1991, Developmental genetics.

Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors.

A. Kiselyov, Eugene L Piatnitski Chekler, R. Katoch-Rouse, 2008, Bioorganic & medicinal chemistry letters.

Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway.

F. Zindy, I. Stamenkovic, J. Jorcano, 1997, Genes & development.

Role of prolactin in growth of the rat mammary tumor MTW9

J. Doody, J. Mandeli, V. Hollander, 2007, International journal of cancer.

Characterization by chromatofocusing of estrogen receptors from rat mammary tumor MTW9.

J. Doody, V. Hollander, J. Cryan, 1989, Journal of the National Cancer Institute.

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

U. Rodeck, Yan Wu, K. Busam, 2009, Cancer research.

Interaction of transforming growth factor-beta receptor I with farnesyl-protein transferase-alpha in yeast and mammalian cells.

J. Massagué, J. Doody, F. Liu, 1996, The Journal of biological chemistry.